Hydronidone

China's NMPA has approved Gyre Therapeutics' clinical trial application to evaluate pirfenidone for treating radiation-induced lung injury and immune-related pneumonitis in cancer patients.

Mineralys Therapeutics has priced its public offering at $13.50 per share, raising approximately $175 million to fund the clinical development of lorundrostat, its aldosterone synthase inhibitor.

Gyre Therapeutics expects topline results from its Phase 3 trial of F351 for Chronic Hepatitis B-associated liver fibrosis in China during Q1 2025.

Gyre Therapeutics reported Q3 2024 revenues of $25.5 million, a decrease from $32.0 million in Q3 2023, alongside a net income of $2.9 million.

Gyre Therapeutics completed its pivotal Phase 3 trial of F351 for chronic hepatitis B-associated liver fibrosis in China, with topline data expected in Q1 2025.